SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHeSYS study

Saved in:
Bibliographic Details
Published inAnnals of hepatology Vol. 13; no. 2; pp. 303 - 304
Main Authors D’heygere, François, George, Christophe, Habersetzer, François, Tripathi, Davender, Pan, Calvin Q, Giron, Jose A, Schmitz, Manuela, Tatsch, Fernando
Format Journal Article
LanguageEnglish
Published Mexico Elsevier 01.03.2014
Subjects
Antiviral Agents - therapeutic use
Cohort Studies
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Gastroenterology and Hepatology
Genotype
Hepacivirus - genetics
Hepatitis C - blood
Hepatitis C - drug therapy
Human health and pathology
Humans
Interferon-alpha - therapeutic use
International Cooperation
Life Sciences
Male
Middle Aged
Polyethylene Glycols - therapeutic use
Pragmatic Clinical Trials as Topic
Recombinant Proteins - therapeutic use
Ribavirin - therapeutic use
RNA, Viral - blood
Treatment Outcome
Viral Load
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:1665-2681
DOI:10.1016/S1665-2681(19)30896-8